Trial intelligence / Profile preview

Cancer Stem Cell Vaccine in Pancreatic Cancer

NCT02074046Phase 2Completed

Sponsor
Fuda Cancer Hospital
Start
Feb 2014
Primary completion
Mar 2015
Countries
1
01

Overview

Phase 2, randomised trial in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Number of participants with adverse events at 3 months. Started Feb 2014; status: completed.

02

Conditions

pancreatic adenocarcinoma (PDAC)

Beyond the preview

Go deeper on NCT02074046.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT02074046.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call